MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3233/jnd-230162

Медицинская библиотека · Journal of neuromuscular diseases · 2024

Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.

Cornell Nikki, Childs Anne-Marie, Wraige Elizabeth, Munot Pinki, Ambegaonkar Gautam, Chow Gabriel, Hughes Imelda, Illingworth Marjorie, Majumdar Anirban, Marini-Bettolo Chiara, Parasuraman Deepak, Spinty Stefan, Willis Tracey, Scoto Mariacristina, Baranello Giovanni, Paediatric UK Risdiplam EAMS Working Group

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Spinal muscular atrophy (SMA) is a progressive neuromuscular disease caused by mutations in Survival motor neuron 1 (SMN1) gene, leading to reduction in survival motor neuron protein (SMN), key for motor neuron survival and function in the brainstem and spinal cord. Risdiplam is an orally administered SMN2-splicing modifier which increases production of functional SMN protein. Risdiplam was offered in the UK under early access to medicines scheme (EAMS) to SMA type 1 and 2 patients aged 2 months and older, not suitable for authorised treatments from September 2020 to December 2021.

OBJECTIVE

To describe the largest paediatric European real-world set of data on patients' characteristics and short-term safety for risdiplam in Great Britain through EAMS.

METHODS

We collated data from SMA REACH UK a national clinical and research network for all patients enrolled onto EAMS and assessed all submitted adverse events.

RESULTS

Of the 92 patients; 78% were Type 2 SMA, mean age 10.9 years, range 0-17 years. 56 were treatment naïve, 33 previously treated; of these 25 had received nusinersen, 3 previous treatment unknown. Sixty adverse events (AEs) were reported occurring in 34 patients. The commonest were respiratory tract infections and gastrointestinal disturbance. Four life-threatening events were reported with 2 deaths and permanent cessation of risdiplam in 3 patients.Overall, 38/60 AEs were considered unrelated to risdiplam, 10/60 related to risdiplam and for 12/60 causality not specified.

CONCLUSIONS

This study found a safety profile similar to clinical trials with no new safety concerns identified. With the restricted eligibility of onasemnogene abeparvovec and complications of nusinersen administration, EAMS allowed access or continued treatment to naïve patients or patients no longer suitable for approved medications. Collection of longitudinal data for this complex population is needed, to provide greater insights into risdiplam's role in addressing patients' needs into the future.

Для цитирования: Cornell Nikki, Childs Anne-Marie, Wraige Elizabeth, Munot Pinki, Ambegaonkar Gautam, Chow Gabriel, Hughes Imelda, Illingworth Marjorie, Majumdar Anirban, Marini-Bettolo Chiara, Parasuraman Deepak, Spinty Stefan, Willis Tracey, Scoto Mariacristina, Baranello Giovanni, Paediatric UK Risdiplam EAMS Working Group. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.. Journal of neuromuscular diseases. 2024. DOI: 10.3233/jnd-230162.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.